RNA:NSD-Avidity Biosciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 46.73

Change

-0.39 (-0.83)%

Market Cap

USD 5.11B

Volume

1.06M

Analyst Target

USD 43.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.61 (+0.94%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-16.67 (-2.03%)

USD 92.70B
ARGX argenx NV ADR

+5.40 (+0.91%)

USD 35.81B
ALNY Alnylam Pharmaceuticals Inc

-4.35 (-1.62%)

USD 34.69B
BGNE BeiGene Ltd

+1.81 (+0.93%)

USD 22.85B
MRNA Moderna Inc

-1.33 (-3.06%)

USD 21.00B
UTHR United Therapeutics Corporatio..

-0.42 (-0.10%)

USD 16.70B
RPRX Royalty Pharma Plc

-0.15 (-0.58%)

USD 16.11B
INCY Incyte Corporation

-0.10 (-0.12%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.29 (-6.21%)

USD 13.75B

ETFs Containing RNA

GNOG:LSE Global X Genomics & Biote.. 6.12 % 0.00 %

+0.05 (+-1.26%)

USD 8.22M
GN0M:XETRA Global X Genomics & Biote.. 5.74 % 0.00 %

+0.07 (+-1.26%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 5.74 % 0.00 %

-0.09 (-1.26%)

USD 5.93M
SURI Simplify Propel Opportuni.. 3.41 % 0.00 %

-0.94 (-1.26%)

N/A
SBIO ALPS Medical Breakthrough.. 3.33 % 0.50 %

-0.53 (-1.26%)

USD 0.13B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.03 (+-1.26%)

USD 0.08B
DXSP:F Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

-0.02 (-1.26%)

N/A
MOON 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 416.35% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 416.35% 99% N/A 99% N/A
Trailing 12 Months  
Capital Gain 650.08% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 650.08% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 36.77% 73% C 83% B
Dividend Return 36.77% 73% C 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 161.66% 28% F 15% F
Risk Adjusted Return 22.75% 79% B- 56% F
Market Capitalization 5.11B 95% A 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector